The Penicillins and Streptomycins dosage market in the US exhibited varying trends from 2012 to 2022. The market experienced fluctuations: a decline in 2013 (-7.82%), a significant increase in 2016 (25.33%), and another downturn in 2018 (-14.79%). The market valued approximately $4.28 billion in 2023. Over the last five years, the compound annual growth rate was -1.83%, indicating a generally stagnant trend with some volatility.
Looking forward, future trends to watch include innovations in antibiotic alternatives, government policies on antibiotic usage, and potential breakthroughs in treating antibiotic-resistant bacteria, which could shape market dynamics.
How does the United States rank in Penicillins and Streptomycins in Dosage Market Size Value?
| # | 33 Countries | US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United States | 4,303,400,000 | 2023 | +0.61% | +1.48% | |
| 2 | 2 United Kingdom | 730,000,000 | 2023 | -1.31% | -1.45% | View data |
| 3 | 3 France | 717,200,000 | 2023 | -1.91% | +0.034% | View data |
| 4 | 4 Italy | 622,330,000 | 2023 | -3.96% | -4.86% | View data |
| 5 | 5 Germany | 476,270,000 | 2023 | +1.03% | +1.1% | View data |
